Daniel P Uccello, Age 4988 Ashley Ln, Colchester, CT 06415

2021001, Jan 21, 2021

Mar 14, 2019

16/980616

- New York NY, US
Matthew Frank Brown - Stonington CT, US
Ye Che - Niantic CT, US
Richard Andrew Ewin - Kalamazoo MI, US
Timothy Allan Johnson - Vicksburg MI, US
Michael Joseph Melnick - Portage MI, US
Justin Ian Montgomery - Ledyard CT, US
Mark Stephen Plummer - Westbrook CT, US
Loren Michael Price - Pensacola FL, US
Usa Reilly - New Haven CT, US
Daniel Uccello - Colchester CT, US

Pfizer Inc. - New York NY

C07F 9/58
C07F 5/02
A61P 31/04

The present invention is directed to a new fluoro-pyridinone hydroxamic acid phosphates and boronates of Formulae I, II and IIIwherein Q is selected from the group consisting of —P(O)(OH), —P(O)(OH)(OM), —P(O)(OM)and —P(O)(O)M; M at each occurrence is a pharmaceutically acceptable monovalent cation; and M is a pharmaceutically acceptable divalent cation and their use as LpxC inhibitors and, more specifically, their use to treat bacterial infections.

2021001, Jan 21, 2021

Mar 14, 2019

16/980473

- New York NY, US
Ye Che - Niantic CT, US
Anthony Marfat - Mystic CT, US
Michael Joseph Melnick - Portage MI, US
Justin Ian Montgomery - Ledyard CT, US
Timothy Allan Johnson - Vicksburg MI, US
Richard Andrew Ewin - Kalamazoo MI, US
Daniel Paul Uccello - Colchester CT, US
Usa Reilly - West Haven CT, US
Tamim Fehme Braish - Groton CT, US

C07F 9/6558
C07F 9/58
C07F 5/04
A61P 31/04

The present invention is directed to new pyridinone or pyrimidinone hydroxamic acid phosphates of Formula (1) and boronates of Formula (2), stereoisomers thereof;wherein Q is selected from the group consisting of —P(O)(OH), —P(O)(OH)(OM), —P(O)(OM)and —P(O)(O)M; M at each occurrence is a pharmaceutically acceptable monovalent cation; and M is a pharmaceutically acceptable divalent cation; X is CH or N; and Z is as defined herein; and their use as LpxC inhibitors and, more specifically, their use to treat bacterial infections.

2020026, Aug 20, 2020

Jun 14, 2018

16/625202

- New York NY, US
Michael Aaron Brodney - Newton MA, US
Matthew Frank Brown - Stonington CT, US
Christopher Ryan Butler - Canton MA, US
Adam Matthew Gilbert - Guilford CT, US
Erik Alphie Lachapelle - Uncasville CT, US
Laura Ann McAllister - Arlington MA, US
Daniel Paul Uccello - Colchester CT, US
Lei Zhang - Auburndale MA, US

C07D 471/04
A61P 25/28
A61P 25/30
A61P 25/18

The present invention provides, in part, compounds of Formula I, or an N-oxide thereof, or a pharmaceutically acceptable salt of the compound or the N-oxide, wherein: (R)a, (R)b, (R)c, L, A, and E are as described herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, N-oxides, or salts, and their uses for treating M4-mediated (or M4-associated) disorders including, e.g., Alzheimer's Disease, schizophrenia (e.g., its cognitive and negative symptoms), pain, addiction, and a sleep disorder.